The latest developments in peptide science, regulatory updates, and research breakthroughs relevant to the field.
Cambridge-based Parabilis Medicines closed an oversubscribed $305 million Series F financing round to advance zolucatetide, a first-in-class peptide...
A peer-reviewed study published in EMBO Molecular Medicine demonstrates that the tetrapeptide CAQK reduces inflammation, decreases cell death, and improves...
A randomized, double-blind, placebo-controlled Phase IIb trial (ELAD) published in Nature Medicine reports that the GLP-1 receptor agonist liraglutide...
The FDA declared the semaglutide shortage resolved in February 2025, triggering restrictions on compounding pharmacies that had been producing the GLP-1...
The compounds discussed on this website are peptides documented in scientific literature. The information provided is for educational and informational purposes only. These compounds are not dietary supplements, food products, or over-the-counter medications. All compound profiles reference published research and analytical standards including HPLC purity analysis and mass spectrometry identity confirmation.
The information provided on this website, including compound profiles, mechanism of action explanations, research summaries, dosage information, and educational content, is for informational and educational purposes only. This information does not constitute medical advice, diagnosis, or treatment recommendations. No content on this website should be interpreted as a substitute for professional medical advice, diagnosis, or treatment.
All peptide compounds discussed on this website should only be used under the supervision of a qualified specialist. A healthcare provider should evaluate individual health status, medical history, current medications, and specific health objectives before any peptide use. Self-administration of research peptides without medical supervision is strongly discouraged and may pose significant health risks.
Individual responses to peptide compounds vary significantly based on genetics, age, body composition, existing health conditions, concurrent medications, and other biological factors. Dosage information provided on this website represents general research ranges and should not be used for self-dosing. A qualified specialist should determine the appropriate compound, dosage, administration route, cycle duration, and monitoring protocol based on individual health assessment.
Peptide Science Thailand assumes no liability for the misuse of information provided on this website. The content is provided for educational purposes only. Users are responsible for ensuring they work with qualified healthcare providers before using any peptide compounds discussed herein. Peptide Science Thailand is not responsible for adverse effects resulting from use without proper medical oversight.
Many peptides discussed here have not been evaluated or approved by the FDA for therapeutic use unless specifically noted (e.g., Tesamorelin, PT-141). The regulatory status of peptide compounds varies by jurisdiction. Some compounds discussed on this website are approved medications in other countries (e.g., Semax and Selank in Russia). This content is for informational and educational purposes only. Users are responsible for understanding and complying with all applicable laws and regulations in their jurisdiction.